Skip to main content

Table 1 JIA ACR50/70 responses and percentage change from baseline in components,a mean ± SD

From: PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH

 

All TCZ (N = 82)

 

Wk 40

Wk 104

JIA ACR70 responders,a n (%)

65 (79.3)

71 (86.6

JIA ACR90 responders,a n (%)

41 (50.0)

58 (70.7)

Active joints (0-71)

-82.4 ± 24.9

-87.7 ± 27.1

Joints with limitation in ROM (0-67)

-73.5 ± 30.7

81.3 ± 31.7

Patient globalc (VAS 0-100 mm)

-62.5 ± 76.3

-75.4 ± 43.8

Physician global (VAS 0-100 mm)

-85.3 ± 16.8

-89.7 ± 23.7

CHAQ-DI (0-3)

-66.0 ± 44.7

-76.7 ± 34.7

ESR (mm/h)

-76.5 ± 22.0

-76.2 ± 27.3

  1. aPts who withdrew are excluded. bPts who withdrew due to non-safety reasons are non-responders. Pts who withdrew due to safety are included using last observation carried forward. cParent-rated.